{"id":45243,"date":"2022-06-13T20:13:26","date_gmt":"2022-06-13T18:13:26","guid":{"rendered":"https:\/\/newserver.fyb.de\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/"},"modified":"2022-06-14T16:45:31","modified_gmt":"2022-06-14T14:45:31","slug":"eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/","title":{"rendered":"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics"},"content":{"rendered":"

Munich \u2014 Baker McKen\u00adzie advi\u00adsed Ariceum Thera\u00adpeu\u00adtics (Ariceum) on the successful closing of a EUR 25 million Series A finan\u00adcing round led by EQT Life Scien\u00adces (form\u00aderly LSP) and Health\u00adCap, and on the acqui\u00adsi\u00adtion of assets from Ipsen Pharma.<\/p>\n

Ariceum is a priva\u00adtely held biotech\u00adno\u00adlogy company deve\u00adlo\u00adping a novel, first-in-class radio\u00adphar\u00admaceu\u00adti\u00adcal product for the diagno\u00adsis and targe\u00adted radia\u00adtion therapy of certain diffi\u00adcult-to-treat cancers. The company was foun\u00added by EQT Life Scien\u00adces<\/strong> (form\u00aderly LSP) and Health\u00adCap<\/strong>, which also led the over\u00adsub\u00adscri\u00adbed finan\u00adcing round in which Pureos Bioven\u00adtures<\/strong>also parti\u00adci\u00adpa\u00adted. Ipsen trans\u00adfer\u00adred assets and all rights to them to the company.<\/p>\n

\u201cToge\u00adther with our client and our team of specia\u00adli\u00adzed corpo\u00adrate, biotech\u00adno\u00adlogy and life scien\u00adces lawy\u00aders, we succee\u00added in secu\u00adring finan\u00adcing, paving the way for the deve\u00adlo\u00adp\u00adment of a therapy for pati\u00adents suffe\u00adring from certain diffi\u00adcult-to-treat cancers,\u201d commen\u00adted Julia Braun, LL.M., the lead part\u00adner on the transaction.<\/p>\n

Ariceum is led by a highly expe\u00adri\u00aden\u00adced manage\u00adment team with a strong track record and exper\u00adtise in clini\u00adcal trials, syste\u00admic radio\u00adthe\u00adrapy and radio-phar\u00admaceu\u00adti\u00adcal deve\u00adlo\u00adp\u00adment, as well as in the launch and commer\u00adcia\u00adliza\u00adtion of diagno\u00adstic and thera\u00adpeu\u00adtic products in a variety of indi\u00adca\u00adti\u00adons worldwide.<\/p>\n

Baker McKen\u00adzie\u2019s Corporate\/M&A and Life Scien\u00adces team regu\u00adlarly advi\u00adses phar\u00admaceu\u00adti\u00adcal compa\u00adnies, finan\u00adcial and stra\u00adte\u00adgic inves\u00adtors, and early-stage biotech\u00adno\u00adlogy compa\u00adnies on dome\u00adstic and inter\u00adna\u00adtio\u00adnal health\u00adcare transactions.<\/p>\n

Most recently, Baker McKen\u00adzie advi\u00adsed, among others, Andera Part\u00adners, Evotec and Fund+ on a EUR 60 million Series B finan\u00adcing of Tubu\u00adlis GmbH, Alle\u00adcra Thera\u00adpeu\u00adtics on an exclu\u00adsive license and supply agree\u00adment with ADVANZ PHARMA, MODAG on a stra\u00adte\u00adgic colla\u00adbo\u00adra\u00adtion with Teva, Chord Thera\u00adpeu\u00adtics on its sale to Merck KGaA, LSP as lead inves\u00adtor in a EUR 20 million Series A equity finan\u00adcing of Inno\u00adva\u00adtive Mole\u00adcu\u00adles, Numab Thera\u00adpeu\u00adtics in a CHF 100 million cross-over finan\u00adcing, Cata\u00adlYm in a EUR 50 million Series B finan\u00adcing led by Vesa\u00adlius Capi\u00adtal, Casdin Capi\u00adtal as lead inves\u00adtor in DNA Scrip\u00adt\u2019s USD 50 million exten\u00added Series B equity finan\u00adcing round, and Chr. Hansen Holding in its acqui\u00adsi\u00adtion of Jenne\u00adwein Biotechnology.<\/p>\n

Legal advi\u00adsor Ariceum Thera\u00adpeu\u00adtics: Baker McKenzie<\/strong><\/p>\n

Lead: Corporate\/M&A: Julia Braun, LL.M.<\/strong> (Part\u00adner, Munich)
\nTeam: Corporate\/M&A: Dr. Marcus Meese (Part\u00adner, Munich), Dr. Katja Heuter\u00adkes (Coun\u00adsel, Munich), Dr. Julia Rossi\u00e9 (Asso\u00adciate, Munich)
\nEmploy\u00adment: Dr. Matthias K\u00f6hler (Part\u00adner, Berlin), Felix Arnold, Dr. Harasch Yakubi (both Asso\u00adcia\u00adtes, Berlin), Amelie Czekalla (Asso\u00adciate, Frankfurt)
\nIP: Dr. Markus Hecht (Coun\u00adsel, Frankfurt)
\nTax: Thomas Gierath (Part\u00adner, Munich), Vikto\u00adria Ritter (Asso\u00adciate, Munich), Jochen Meyer-Burow (Part\u00adner, Frank\u00adfurt), Ariane Schaaf (Coun\u00adsel, Frankfurt)<\/p>\n

About Baker McKenzie<\/strong><\/p>\n

Complex busi\u00adness chal\u00adlenges require a holi\u00adstic response across diffe\u00adrent markets, sectors and juris\u00addic\u00adtions. Baker McKen\u00adzie\u2019s solu\u00adti\u00adons for clients are accom\u00adpa\u00adnied by seam\u00adless advice, under\u00adpin\u00adned by in-depth prac\u00adtice and indus\u00adtry know\u00adledge as well as excel\u00adlent local market insights. In more than 70 offices world\u00adwide, we work with our clients to provide solu\u00adti\u00adons for a connec\u00adted world.<\/p>\n

In Germany, around 200 lawy\u00aders in Berlin, D\u00fcssel\u00addorf, Frankfurt\/Main and Munich repre\u00adsent the inte\u00adrests of their clients with proven profes\u00adsio\u00adnal exper\u00adtise and inter\u00adna\u00adtio\u00adnal expe\u00adri\u00adence. As one of the leading German law firms, Baker McKen\u00adzie advi\u00adses natio\u00adnal and inter\u00adna\u00adtio\u00adnal compa\u00adnies and insti\u00adtu\u00adti\u00adons in all areas of commer\u00adcial law.<\/p>\n","protected":false},"excerpt":{"rendered":"

Munich \u2014 Baker McKen\u00adzie advi\u00adsed Ariceum Thera\u00adpeu\u00adtics (Ariceum) on the successful closing of a EUR 25 million Series A finan\u00adcing round led by EQT Life Scien\u00adces (form\u00aderly LSP) and Health\u00adCap, and on the acqui\u00adsi\u00adtion of assets from Ipsen Pharma. Ariceum is a priva\u00adtely held biotech\u00adno\u00adlogy company deve\u00adlo\u00adping a novel, first-in-class radio\u00adphar\u00admaceu\u00adti\u00adcal product for the diagnosis [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":45292,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1369],"tags":[],"class_list":["post-45243","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-investors"],"yoast_head":"\nEQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Munich \u2014 Baker McKen\u00adzie advi\u00adsed Ariceum Thera\u00adpeu\u00adtics (Ariceum) on the successful closing of a EUR 25 million Series A finan\u00adcing round led by EQT Life Scien\u00adces (form\u00aderly LSP) and Health\u00adCap, and on the acqui\u00adsi\u00adtion of assets from Ipsen Pharma. Ariceum is a priva\u00adtely held biotech\u00adno\u00adlogy company deve\u00adlo\u00adping a novel, first-in-class radio\u00adphar\u00admaceu\u00adti\u00adcal product for the diagno\u00adsis […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T18:13:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-14T14:45:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png\" \/>\n\t<meta property=\"og:image:width\" content=\"9058\" \/>\n\t<meta property=\"og:image:height\" content=\"4833\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics\",\"datePublished\":\"2022-06-13T18:13:26+00:00\",\"dateModified\":\"2022-06-14T14:45:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/\"},\"wordCount\":524,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png\",\"articleSection\":[\"General\",\"Featured\",\"Private equity\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Investors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/\",\"url\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/\",\"name\":\"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png\",\"datePublished\":\"2022-06-13T18:13:26+00:00\",\"dateModified\":\"2022-06-14T14:45:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png\",\"width\":2048,\"height\":1093},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics - FYB Financial Yearbook","og_description":"Munich \u2014 Baker McKen\u00adzie advi\u00adsed Ariceum Thera\u00adpeu\u00adtics (Ariceum) on the successful closing of a EUR 25 million Series A finan\u00adcing round led by EQT Life Scien\u00adces (form\u00aderly LSP) and Health\u00adCap, and on the acqui\u00adsi\u00adtion of assets from Ipsen Pharma. Ariceum is a priva\u00adtely held biotech\u00adno\u00adlogy company deve\u00adlo\u00adping a novel, first-in-class radio\u00adphar\u00admaceu\u00adti\u00adcal product for the diagno\u00adsis […]","og_url":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2022-06-13T18:13:26+00:00","article_modified_time":"2022-06-14T14:45:31+00:00","og_image":[{"width":9058,"height":4833,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png","type":"image\/png"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics","datePublished":"2022-06-13T18:13:26+00:00","dateModified":"2022-06-14T14:45:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/"},"wordCount":524,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png","articleSection":["General","Featured","Private equity","News","Lawyers\/Tax-advisors\/Auditors","Investors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/","url":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/","name":"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png","datePublished":"2022-06-13T18:13:26+00:00","dateModified":"2022-06-14T14:45:31+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/06\/eqt-orange-jpeg-1-674819805.png","width":2048,"height":1093},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/eqt-and-healthcap-lead-series-a-for-eur-25-million-for-ariceum-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/45243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=45243"}],"version-history":[{"count":2,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/45243\/revisions"}],"predecessor-version":[{"id":45295,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/45243\/revisions\/45295"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/45292"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=45243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=45243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=45243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}